Carcinoma of the breast in males

Donegan, William L.; Redlich, Philip N.; Lang, Jing Yu; Gall, Matthew T.

doi:10.1002/(sici)1097-0142(19980801)83:3<498::aid-cncr19>3.0.co;2-r

Cited by 181 publications

(44 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of comorbidities increased with age, which likely contributed to the decreased OS in MBC than FBC. Donegan et al [16] reported that the high rate of post-treatment mortality from comorbidities, such as heart disease or other cancer types, was a major contributor to the poor survival observed in MBC. In our population-based comparison, MBC had more advanced stages (stages II-IV), lower grades, larger sizes, more lymph node and distant metastases than FBC.…”

Section: Discussionmentioning

confidence: 99%

Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype

Zhu

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Background & AimsSubstantial controversy exists regarding the differences in tumor subtypes between male breast cancer (MBC) and female breast cancer (FBC). This is the largest population-based study to compare MBC and FBC patients.MethodsUsing data obtained by the Surveillance, Epidemiology, and End Results (SEER) program from 2010-2012, a retrospective, population-based cohort study was conducted to investigate tumor subtype-specific differences in various characteristics, overall survival (OS) and breast cancer-specific mortality (BCSM) between males and females.ResultsIn all, 181,814 BC patients (1,516 male and 180,298 female) were eligible for this study. The male patients were more likely to be black, older, and have lower histological grades, more advanced stages, larger tumors, more lymph node and distant metastases and human epidermal growth factor receptor 2 (HER2)-negative tumors (each p<0.05). A matched analysis showed that the 2-year OS was 91.2% and 93.7% and that the BCSM was 2.2% and 2.5% for male and female patients, respectively. The univariate analysis showed that male triple-negative (TN), hormone receptor (HoR)-positive/HER2-positive and HoR-positive/HER2-negative patients had poorer OS (p <0.01). Meanwhile, the HoR-positive/HER2-positive and TN subtypes were associated with a higher BCSM in MBC patients (p<0.01). The multivariate analysis revealed that TN MBC patients had poorer OS and BCSM (p<0.05). Simultaneously, the results showed that male patients in the HoR-positive/HER2-negative subgroup were less likely to die of BC when adjusting for other factors (p<0.05).ConclusionsThe analysis of 2-year OS and BCSM among the BC subtypes showed clear differences between MBC and FBC patients with the TN subtype; these differences warrant further investigation

show abstract

Section: Discussionmentioning

confidence: 99%

Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype

Zhu

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Older age at diagnosis is associated with a higher prevalence of comorbidities, which likely explains the overall poorer survival among male compared with female breast cancer patients. Donegan et al [8] reported that a major contributor to the poor survival in male breast cancer patients was from the high rate of post-treatment mortality from comorbid disease. Approximately one third of post-treatment deaths were due to heart disease or other non-breast cancers [8].…”

Section: Discussionmentioning

confidence: 99%

Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration

et al. 2010

View full text Add to dashboard Cite

Background Male breast cancer accounts for less than 1% of all breast cancers, yet males have a worse prognosis than females with breast cancer. Methods Using the 1988–2003 Surveillance, Epidemiology, and End Results Program data, we conducted a retrospective, population-based cohort study to investigate stage-specific differences in breast cancer-specific and all-cause mortality between males and females. We calculated adjusted hazard ratios (aHR) and 95% confidence intervals (CI) using Cox regression models to compare breast cancer-specific and all-cause mortality by stage between males and females, controlling for potential confounding variables. Results There were 246,059 patients with a first, single, primary breast cancer (1,541 [0.6%] male; 244,518 [99.4%] female). Compared with females, males were more likely to be older, black, married, diagnosed at more advanced stages, and treated with mastectomy (each p<0.001). Males also were more likely to have lower grade and estrogen/progesterone receptor positive tumors (each p<0.001). After controlling for confounders, males were more likely to die from their breast cancer when compared to females, only if diagnosed with stage I disease (aHR 1.72, CI: 1.15–2.61). For all-cause mortality, males were more likely than females to die at each stage of disease except stage IV. Conclusion Although all-cause mortality was higher for men than women at all stages of non-metastatic breast cancer, higher male breast cancer-specific mortality was attributed to poorer survival in stage I disease. However, this statistical difference is unlikely to be clinically relevant and attributable to in-stage migration.

show abstract

“…Some of the risk factors implicated include diet (10), alcohol intake, obesity (11), tobacco abuse, and conditions associated with increased estrogen or decreased androgen, medications, or radiation exposure (12). Similar to the case of breast carcinoma in females, a family history of breast cancer in men or women MBC patients had fewer months of survival than did control patients.…”

Section: Discussionmentioning

confidence: 99%

Male Breast Carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with Treatment and Survival, a Study of 65 Cases

et al. 2002

View full text Add to dashboard Cite

Male breast cancer is rare, and experience of it in any single institution is limited. Our current understanding regarding its biology, natural history, and treatment strategies has been extrapolated from its female counterpart. The aim of this study is to evaluate the expression patterns of estrogen receptor (ER), progesterone receptor (PR), MiB1 (Ki67), Her-2/neu (c-erbB2), and p53 and to correlate them with the prognosis, presentation, staging, management, and survival/outcome in male breast carcinoma identified through the Veterans Administration nationwide cancer registry. Sixty-five cases of male breast cancer were reviewed for classification. Tumor blocks were requested from each institution for immunohistochemical staining and evaluation of ER, PR, p53, Her2-neu, and MiB1. Seventeen ageand disease-matched male veteran patients with breast gynecomastia were used as controls. Traditional prognostic data were collected for comparison with female breast cancers (i.e., age, lymph node status, clinical staging, tumor size, histological grade, and disease-free and overall survival). Male breast carcinoma had worse disease-free survival than controls (P ‫؍‬ .03). The clinical stage regardless of tumor size or lymph node metastasis was the single most significant prognostic factor (P < .0001). ER-positive patients appeared to have a better survival than did ER-negative patients (P ‫؍‬ .03, univariate; P not significant in multivariate) and did not benefit from treatment with tamoxifen (P ‫؍‬ .0027, univariate; P ‫؍‬ .42, multivariate). MiB1 and PR expressions did not correlate with treatment or survival, and p53 was associated with shorter disease free survival (P ‫؍‬ .07, univariate; P ‫؍‬ .047, multivariate). Stage for stage, Her2-neu was associated with shorter disease-free survival (P < .0001) and correlated with positive lymph nodes (P ‫؍‬ .08). Male breast carcinoma is rare, with an estimated 1,000 to 1,400 new cases per year (1). The tumor phenotypic alterations are not well studied, and experience is mainly inferred from that of female breast cancer. Although both diseases have similarities, there are notable differences in risk factors, prognosis, and survival. Reported differences between male and female breast carcinoma have been noted, and male breast carcinoma has a tendency to present at higher clinical stages and with more lymph node metastases (2-4). Many molecular markers are available for the better understanding of female breast cancer tumorigenesis and disease progression and possibly to guide treatment. How-

show abstract

Carcinoma of the breast in males

Cited by 181 publications

References 25 publications

Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype

Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype

Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration

Male Breast Carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with Treatment and Survival, a Study of 65 Cases

Contact Info

Product

Resources

About